circulation levels, forming a potent calcification inhibitory system, whereas decreased levels of functional γ-carboxylated MGP (cMGP) and fetuin-A have been linked to an enhanced calcification environment. [11] [12] [13] [14] [15] A key event in the initiation of VSMC calcification is the release of mineralization-competent extracellular vesicles (EVs), capable of efficiently nucleating hydroxyapatite in the absence of calcification inhibitors, such as MGP. 3, 5, 15 However, the existence of additional calcification inhibitors has been repeatedly suggested. 16, 17 Gla-rich protein (GRP) is a vitamin K-dependent protein 18 whose function and molecular mechanisms of action remain unknown, albeit zebrafish knockdown 19 and knockout mouse 20 studies have been performed. Also, different alternatively spliced transcripts, the function of which remains to be clarified, were shown to exist in mouse/zebrafish 19, 21 and human, 22 highlighting the existence of distinct gene regulation in animal models and humans. However, GRP has been suggested to act as a negative regulator of osteogenic differentiation, 23 a modulator of calcium availability in the ECM, 18, 24 and as a potential inhibitor of soft tissue calcification in connective tissues. 24 In concordance, its potential calcium-binding properties and association with calcification processes have been demonstrated through immunohistochemical and in vitro studies, showing (1) high levels of protein accumulation at the sites of pathological calcification 22, 24, 25 and (2) its capacity to directly bind basic calcium phosphate crystals. 25 γ-Carboxylation of human GRP has been recently evidenced using a conformation-specific antibody for the γ-carboxylated GRP (cGRP) conformation, 25 whereas an impaired γ-carboxylation status has been associated with pathological calcification-related diseases, such as osteoarthritis, 22 and certain cancers. 25 In this work, we aimed to study the relationship of GRP, at gene and protein levels, with valvular calcification and VC processes, highlighting GRP function and molecular mechanisms of action.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Upregulation of GRP-F1 in Cardiovascular Tissues Is Associated With Mineral Deposition
The expression pattern of GRP splice variants was qualitatively evaluated by reverse transcription polymerase chain reaction in several fetal and adult tissues composing the cardiovascular system, and showed the preponderancy of GRP-F1 in all tissues analyzed ( Figure I in the online-only Data Supplement). Quantitative analysis of GRP-F1 gene expression determined by quantitative polymerase chain reaction in aorta, aortic valve, and pulmonary valve adult tissues ( Table I in the online-only Data Supplement) showed different levels of expression among each tissue set that, however, correlate with levels of osteocalcin: higher levels of GRP were found in samples presenting higher levels of osteocalcin ( Figure 1A) . Tissue histomorphological evaluation, using hematoxylineosin and von Kossa (VK) stainings, revealed the presence of detectable mineral deposits in 41% of the analyzed samples, which correlates with detectable atherosclerotic lesions at autopsy ( Table I in the online-only Data Supplement) and high levels of osteocalcin expression ( Table I in the online-only Data Supplement). Immunohistochemistry analysis using the CTerm-GRP antibody, recognizing total GRP (tGRP), clearly showed higher levels of protein deposition in calcified positive VK samples from both aorta and aortic valve tissues ( Figure 1B) , whereas in noncalcified normal histopathologic (hematoxylin-eosin [HE]) areas, GRP was sporadically detected in association with VSMCs in aorta and VICs in aortic valve ( Figure 1B ). In these samples, no differences were observed between cGRP and undercarboxylated GRP (ucGRP) accumulation; moreover, the distribution patterns of both conformations were similar to that of tGRP ( Figure  IIA 
GRP Accumulation Is Associated With Calcification and VIC Disarray in CAVD
Histological characterization of 11 CAVD samples analyzed ( Table II in the online-only Data Supplement), using HE and VK stainings, revealed a highly heterogeneous phenotype, with heterogeneous disruption of ECM, VIC disorganization, and calcification ( Figure III in the online-only Data Supplement), as previously described. 1, 2, 7 The accumulation pattern of the different GRP protein forms associated with CAVD was determined through immunohistochemistry using the conformation-specific cGRP and ucGRP antibodies ( Figure 2 ). Levels and patterns of GRP accumulation were found heterogeneously among the CAVD group. In the regions of disperse mineralization, GRP was mainly detected in association with mineral and sporadic VICs (Figure 2A-2C ), whereas higher GRP accumulation was found to be associated with atheromatous regions, heavy calcified areas, and high cellularity ( Figure 2D-2O ). In atheromatous areas, all GRP forms were detected with a similar pattern surrounding atheroma and localized to specific regions containing the remaining residual mineral ( Figure 2D-2F patterns were observed in the regions of massive calcification in nondecalcified tissue sections, colocalizing with mineral deposits ( Figure IV in the online-only Data Supplement). Foam cells, found in the regions of lipid accumulation mostly present in atheromas surrounding areas, were shown to accumulate tGRP ( Figure 2G ). The lower staining observed for cGRP ( Figure 2H ), when compared with ucGRP ( Figure 2I ), and the colocalization of ucGRP with tGRP indicate ucGRP as the predominant protein form in foam cells. Both cGRP and ucGRP were detected in VICs in the regions of high and disarrayed cellularity although with different patterns of accumulation; whereas ucGRP is mostly found intracellularly in most VICs ( Figure 2L and 2O), cGRP is predominantly localized Of notice, some of the fibroblast-like cells were GRP negative (white arrow head), a pattern confirmed with all antibodies ( Figure 2J -2O). Cells accumulating GRP were mostly assumed as VICs, and although at this stage we cannot rule out the possibility of GRP colocalization with T lymphocytes, the majority of cells accumulating GRP were found to be cluster of differentiation 68 and cluster of differentiation 3 negative (results not shown). Overall, these results indicate that higher GRP accumulation in CAVD is associated with calcification together with VIC disarray and specifically associated with particular VIC populations. Although ucGRP is apparently predominant in CAVD, cGRP seems to be mostly targeted to the sites of calcification. Negative controls showed the absence of signal ( Figure V in the online-only Data Supplement).
GRP, MGP, and Osteocalcin Are Concomitantly Upregulated in CAVD
The GRP gene expression profile in CAVD was evaluated to correlate it with the degree of cellular differentiation and calcification. Gene expression of known osteoblastic, differentiation, and inflammation markers-MGP, osteocalcin, osteopontin, α-smooth muscle actin (αSMA), and tumor necrosis factor-α-is determined in CAVD and non-CAVD groups (Figure 3 ). Although no significant differences in GRP, MGP, and osteocalcin levels were found between samples in each sample group, GRP was clearly upregulated in the majority of CAVD samples with an expression pattern highly similar to that of MGP and osteocalcin. In concordance with the immunohistochemistry results showing specific GRP accumulation in certain VICs, gene expression is higher in the particular set of samples presenting higher levels of MGP and osteocalcin. In contrast, a significant upregulation of osteopontin, αSMA, and tumor necrosis factor-α is shown between all CAVD and non-CAVD samples, indicative of typical stenotic processes occurring in CAVD, characterized by VIC phenotypic transitions. These results suggest that GRP is upregulated in specific differentiation stages of VIC populations, concomitantly expressing MGP and osteocalcin, probably in a later stage of VIC osteochondrogenic differentiation. Gene expression of GRP-F5 and F6 was also analyzed, and the results showed barely detectable expression of both transcripts in the majority of CAVD samples ( Figure VI in the online-only Data Supplement).
GRP, MGP, and Fetuin-A Are Associated With the Mineral Phase of CAVD, Resembling Bone and VC
To characterize GRP protein forms associated with the mineral phase of calcified aortic valves and to further identify additional proteins involved in aortic valve calcification, the mineral-bound proteins (M-P) and 2 protein extracts of the organic matrix (E1 and E2) obtained from calcified aortic valves, were analyzed by SDS-PAGE and Western blot (WB; Figure 4A ) and a clear preponderance of low-molecular weight proteins associated with the mineral phase (M-P, Figure 4A ). Both GRP and MGP were confirmed to be present mainly in the M-P ( Figure 4B ). Four protein bands were detected with CTerm-GRP and ucGRP antibodies (tGRP and ucGRP in Figure 4B ), corresponding to the protein profile marked as 1, 2, 3, and 4 on SDS-PAGE gel ( Figure 4A ), whereas cGRP antibodies preferably detect band 2 (cGRP in Figure 4B ). In E1 and M-P extracts, a 25-kDa protein band was also detected, particularly with CTerm-GRP and cGRP antibodies, which may either represent intracellular nonprocessed protein or aggregated forms of GRP ( Figure 4B ). Both undercarboxylated MGP and cMGP protein forms were detected in M-P, where 2 main protein bands named 2 and 5 were detected with both specific antibodies ( Figure 4B ). Fetuin-A was found to be present mostly in the M-P and E1 extracts, whereas E2 showed only residual detection ( Figure 4B ). Further identification of proteins present in SDS-PAGE gel slices marked as 1, 2, 3, 4, 5, and 6 was performed by nano-liquid chromatography-mass spectrometry (MS)/MS analysis ( Figure 4C ; Tables IV and V in the onlineonly Data Supplement). Protein identities were confirmed in bands 1 and 2 for GRP, in bands 1 to 5 for MGP, and in band 6 for fetuin-A ( Figure 4C ; Table IV in the online-only Data Supplement), in concordance with WB detections. These results indicate that GRP species present in bands 3 and 4 are predominantly undercarboxylated, although identification by MS was not successful, most possibly because of lower abundance. Identification of additional known osteogenic markers, such as osteopontin, calcium-binding proteins, such as protein S100-A9 (S10A9), and lipid-associated proteins, such as apolipoprotein E, were also identified in the M-P extract ( Table V in the online-only Data Supplement). Identification of Gla residues could not be achieved by liquid chromatography-MS/MS neither for GRP nor for MGP, most possibly because Gla residues may undergo neutral loss of CO 2 from the γ-carboxy carbon, either during ionization by matrix-assisted laser desorption/ionization or after collisioninduced dissociation tandem MS (MS/MS). 26 Overall, our results showed that GRP is associated with the mineral phase of calcified stenotic valves together with other calcification inhibitors known to accumulate at the sites of calcification, both in bone and vascular tissues.
γ-Carboxylated GRP Inhibits Calcification in an Ex Vivo Aortic Calcification Model by Upregulating αSMA and Downregulating Osteopontin Expression
To determine whether GRP directly affects VC and to examine the relevance of its γ-carboxylation status, we adapted an ex vivo model of aortic rings by culturing small human aortic fragments both under control or mineralizing conditions; these cultures were supplemented with either ucGRP or cGRP. Calcification obtained under Ca+P supplementation was characterized by substantial accumulation of calcium deposits along the media, whereas aortic fragments cultured under control conditions had generally no detectable calcification (results not shown); only in a few cases, the control tissues contained some minor disperse calcium spots ( Figure 5A ). After 14 days of in vitro culture, HE staining showed an intact structure of the vessels and an apparently normal VSMC Figure 4 legend) . GRP, cMGP, and Fet-A are detected in both IP-GRP and IP-MGP immunoprecipitants and not in the negative IgG-IP reaction. C, WB analysis of EVs isolated from cultured aortic segments for 3 and 6 days by differential centrifugation at 10 000g and 100 000g, using CTerm-GRP, cMGP, and Fet-A (BioVendor) antibodies. GRP and MGP are only detected in 100 000g isolated EVs and are similarly present under tested conditions at day 3, whereas a strong subsequent reduction is observed after long-term calcifying treatment. D, EVs isolated at 100 000g Figure VIIB and VIIC in the online-only Data Supplement. SD was calculated (n=3), and ANOVA with comparison between groups by Dunnett test was performed. C, αSMA and OPN gene expression determined by quantitative polymerase chain reaction in aortic segments cultured for 14 days under the conditions described above, showing decreased αSMA and increased OPN in calcifying media, whereas cGRP treatment results in increased αSMA and decreased OPN expression relative to Ca+P, to levels similar to control. No significant differences were observed with ucGRP media supplementation. SD was calculated (n>4), and ANOVA with comparison between groups by Dunnett test was performed. Solid and dashed lines represent comparisons relative to Ca+P and to C conditions, respectively. phenotype under all conditions ( Figure VIIA in the online-only Data Supplement); at this stage, no outgrowth or proliferation of VSMCs was observed (results not shown). A significant increase in Ca accumulation was determined in Ca+P relative to control, whereas addition of ucGRP did not significantly affect Ca levels relative to Ca+P (Figure 5B ; Figure VIIB and VIIC in the online-only Data Supplement). However, Ca+P supplemented with 500 ng/mL of cGRP results in a significant decrease in Ca, whereas 250 ng/mL showed a nonsignificant tendency for calcification inhibition (Figure 5B ; Figure VIIB and VIIC in the online-only Data Supplement). Reduction of calcium deposits in vessels treated with 500 ng/mL of cGRP was confirmed by VK staining (Figure 5A ). Different inhibition degrees were obtained in the 3 experiments performed with 500 ng/mL of cGRP (28.2% [ Figure VIIB in the onlineonly Data Supplement], 42.6% [ Figure 5B ], and 50% [ Figure  VIIC in the online-only Data Supplement]) but were found similar to those obtained with 500 ng/mL of both bovine MGP and bovine fetuin-A ( Figure 5B ; Figure VIIB in the onlineonly Data Supplement). Mineralizing conditions induced a decrease of α-SMA and an increase in osteopontin expression, indicative of an osteochondrogenic differentiation occurring in VSMCs, whereas exogenous cGRP is able to induce an increased α-SMA and decreased osteopontin expression relative to Ca+P ( Figure 5C ). Nonsignificant changes were observed with ucGRP treatment ( Figure 5C ). These results clearly show that (1) calcification inhibition is dependent on GRP dosage and γ-carboxylation status, indicating a preponderant role of Gla residues in the calcification inhibitory function of GRP, (2) carboxylated GRP has similar capacity of preventing calcification as the 2 widely accepted VC inhibitors, MGP and fetuin-A, and (3) GRP interferes with the osteochondrogenic differentiation process by retaining VSMCs in a contractile phenotype.
GRP-MGP-Fetuin-A Complex Is Associated With Calcification Sites, and Increased Calcium Loading of VSMC-Derived EVs Is Related to GRP and MGP Depletion
Immunohistochemistry of double-staining experiments, using the respective antibodies, showed the colocalization of (1) cGRP and cMGP, (2) cGRP and fetuin-A, and (3) cMGP and fetuin-A, all in association with the mineral phase (VK, Figure 6A ). These data point to a possible association of the 3 proteins at the sites of calcification. To further test this hypothesis, immunoprecipitation of an M-P extract resuspended in 10 mmol/L of Tris-HCl pH 7.5 was carried out using either CTerm-GRP or cMGP as capture antibodies. Before immunoprecipitation assays, the presence of both GRP and MGP in the Tris-HCl buffer was confirmed by WB because both proteins are known to have poor solubility in neutral buffers. 18, 27 Only part of the initially resuspended proteins was recovered in the soluble fraction, whereas the predominant GRP soluble protein form was detected as a 15-kDa band with the cGRP antibody ( Figure VIII in the online-only Data Supplement). WB analysis of the resulting eluted proteins after GRP and MGP immunoprecipitation assays showed positive detection of the 15-kDa GRP band in the anti-GRP and anti-MGP immunoprecipitates. Control IgG immunoprecipitation gave negative results ( Figure 6B ). In concordance, MGP was also detected in both immunoprecipitation assays ( Figure 6B) and was further identified by liquid chromatography-MS/MS in the eluted GRP-immunoprecipitation proteins (results not shown). Additionally, fetuin-A was detected in both GRP-and MGPimmunoprecipitation eluted proteins, and a residual signal was observed in the IgG-immunoprecipitation reaction, most certainly corresponding to the heavy IgG chain of antibodies ( Figure 6B) . To discard a possible cross-reactivity of cMGP antibody with GRP, immunoprecipitation assays were reproduced as described for M-P extract, using conditioned media of transiently transfected HEK293T cells with GRP-F1-mkate2 fusion protein and the control pmkate2-N plasmid. Protein immunodetection was achieved with the CTerm-GRP antibody showing positive detection of GRP-F1-mkate2 fusion protein only in the GRP-immunoprecipitation eluted proteins ( Figure  IX in the online-only Data Supplement), further confirming the specificity of the immunoprecipitation assays. Overall, these results provide strong evidence for the existence of a GRP-MGP-fetuin-A containing complex at the sites of VC.
Because VC is a process highly related to the mineralization capacity of EVs and to the presence of cMGP and fetuin-A, 3, 5, 9, 15 the association of GRP with EVs in VSMC mineralization was investigated using the developed human vessel ex vivo culture system. EVs were isolated from the media of aortic segments cultured under C and Ca+P conditions, by differential centrifugation after 3 and 6 days in culture, and the presence of GRP, MGP, and fetuin-A was analyzed by WB. Overall, GRP and MGP were only detected in EVs obtained by ultracentrifugation at 100 000g, whereas high levels of fetuin-A were found in Ca+P EVs obtained at both 10 000g and 100 000g ( Figure 6C ). Importantly, although at day 3, levels of GRP and MGP are similar between C and Ca+P, a strong reduction is observed for both proteins under mineralizing conditions at day 6 ( Figure 6C ). This reduction of MGP and GRP loading in EVs is also related to increased EV calcium loading ( Figure 6D ). Further characterization of isolated EVs containing MGP and GRP was performed by scanning electron microscopy, showing a highly homogenous population of small vesicles with an average size range of 65±12 nm that were found positive for cluster of differentiation 9 ( Figure 6E ).
Discussion
In this study, we demonstrated that GRP has a function in calcium homeostasis in the cardiovascular system, most likely by acting as a calcification inhibitor through its calcium chelator and mineral-binding capacity, and involvement in the mineralization competence of VSMC-derived EVs.
VSMCs and VICs synthesize low basal levels of GRP in normal histopathologic human aortas and aortic valves, but its levels of protein accumulation and gene expression highly increase with calcification. Immunohistochemistry results evidence the colocalization of GRP with the mineral phase, whereas gene expression analysis reveals a GRP upregulation concomitant with the osteoblastic marker osteocalcin. The parallel upregulation of GRP with osteocalcin and MGP, and not necessarily with an increase in osteopontin, αSMA, or tumor necrosis factor-α, further suggests an association of GRP with osteoblast-like VICs after myofibroblast-VIC differentiation. VICs are a highly plastic population of valvular resident cells with the ability to differentiate into a variety of other cell types, such as myofibroblasts and osteoblast-like cells with calcifying potential. 1, 2 Under endothelial damage and lipid deposition, inflammation is triggered with consequent macrophage differentiation and accumulation, expressing tumor necrosis factor-α and osteopontin. 1, 28, 29 Inflammatory activity initiates a subpopulation of VICs to differentiate into myofibroblasts expressing αSMA and matrix metalloproteinases. 1, 2 Consequently, disease progression from sclerotic to stenotic states is thought to be driven by the differentiation of myofibroblasts into osteoblast-like cells, with local production of factors, such as osteocalcin, commonly associated with bone and VC. [1] [2] [3] 7 Although abnormal circulating MGP levels have been associated with CAVD, 30 studies of MGP at tissue level in CAVD are lacking. However, MGP expression is known to increase with osteoblast development/maturation and has been considered a late marker of osteoblast-like differentiation in calcifying vascular cells. MGP upregulation in areas of extracellular VC both in vivo 31, 32 and in vitro 33 precludes a mechanism to limit further the extent of calcification through cell differentiation modulation and control of matrix calcification.
We have recently reported that although both cGRP and ucGRP forms possess Ca/P mineral-binding affinity and are present in healthy connective tissues, the increased accumulation of ucGRP is associated with a pathological condition. 22, 25 In concordance, both cGRP and ucGRP were detected in VSMCs and VICs in normal tissues, and highly accumulated at the sites of mineral deposition with relative similar levels. Also, a predominance of ucGRP relative to cGRP was confirmed in CAVD by immunohistochemistry. The pattern of cGRP accumulation further suggests that the reduced amount of cGRP produced may be directed to the sites of calcification where it accumulates probably as a mechanism to control or limit the levels of calcification. In concordance, both GRP species were detected in extracts of mineral-bound proteins derived from calcified aortic valves. The pattern of GRP in WB was shown to be complex with multiple positive bands consistently detected with all available anti-GRP antibodies. The presence of the alternatively spliced variants F5 and F6 in this protein profile can be excluded because their expression was nearly undetectable in both normal and calcified valves. Moreover, the conformation-specific antibodies were raised against synthetic peptides comprising partial Gla/Glu domains, so multiple patterning may represent different degrees of γ-carboxylation, with a predominant γ-carboxylated protein form migrating at 15 kDa. In fact, Gla proteins with different degrees of γ-carboxylation have been shown to alter their migration behavior on SDS-PAGE gels. 34 In addition, the fact that we used a pool of individual aortic valves may have contributed to the high Gla content heterogeneity. GRP identification was confirmed by MS analysis of 2 immunopositive bands. With this approach, we have also identified MGP and fetuin-A as mineral-bound proteins associated with CAVD. Other proteins involved in vascular and bone mineralization (eg, osteopontin) were also identified, providing additional evidence that common mechanisms exist in valvular, VC, and physiological bone mineralization.
The similar patterns of GRP and MGP upregulation, and mineral colocalization shown in CAVD, further support the previously proposed calcification inhibitory function of GRP. More importantly, using an ex vivo model of human vessel culture, we showed that cGRP is able to inhibit the calcification to the same extent as cMGP and fetuin-A. Although a reduction in calcification was observed to some extent with noncarboxylated GRP supplementation, only with cGRP a clear dose-dependent calcification inhibition was obtained, suggesting that γ-carboxylation is essential for GRP's calcification inhibitory function. γ-Carboxylation has been shown to be required for biological activity of vitamin K-dependent proteins whose function is known, and under-or uncarboxylated species are generally regarded as proteins with low or no functional activity. 17, 32, 35, 36 This has been extensively shown for MGP, the inhibitory function of which is highly dependent on its γ-carboxylation status, in particular, in VSMCs. 3, 5, 9 In our model, vessel calcification was characterized mostly by a medial localization, decreased α-SMA, and simultaneously increased osteopontin expression. These events are counteracted by cGRP through the upregulation of αSMA and downregulation of osteopontin, indicating a protective effect on the Ca/P-induced effect on VSMCs, shifting from a contractile to a synthetic osteochondrogenic phenotype. High extracellular calcium has been shown to act as a key trigger for VSMC calcification by activation of intracellular signaling pathways that culminate in the secretion of mineralization-competent EVs. 5 Inhibition of calcium or cytosolic calcium chelation efficiently prevents VSMC calcification. 15 It is conceivable to propose that addition of exogenous cGRP to VSMCs could act as a calcium chelator agent, decreasing extracellular calcium levels and reducing calcification. In addition, we have previously shown that GRP can directly bind basic calcium phosphate crystals in vitro, and in this way, it may interfere with crystal growth or maturation through a similar mechanism previously proposed for the calcification inhibitory activity of MGP. 25 Altogether, our in vitro and ex vivo results show that although both cGRP and ucGRP have calcium mineral affinity, cGRP is a more efficient VC inhibitor.
To uncover additional mechanisms involving GRP in cardiovascular calcification, we further explored the relationship between GRP and MGP. Our results from immunoprecipitation assays strongly suggest that GRP is part of a larger complex containing MGP and fetuin-A, acting at the sites of calcification. A relationship between MGP and fetuin-A has been documented previously, at both circulation 13 and tissue levels. 12 It is known that VC is a process initiated with the deposition in the ECM of basic calcium phosphate containing EVs derived from VSMCs, forming a nidus of calcification in a process similar to bone mineralization. 3, 5, 9, 11, 15 It has been reported that under normal conditions, VSMC-derived EVs do not calcify because of their loading with mineralization inhibitors, such as cMGP and fetuin-A, that act to block mineral nucleation. 3, 5, 9, 11, 15 In this context, it was important to further understand whether GRP was also involved in EV biogenesis or mineralization competence associated with ECM calcification. The presence of GRP was confirmed in EVs released by aortic fragments, with <100-nm size and expressing cluster of differentiation 9, consistent with exosome profiling. 37, 38 Importantly, these EVs were also loaded with MGP and fetuin-A under control conditions, whereas MGP and GRP EV contents dramatically decrease after longterm calcifying conditions, concomitantly with an increase in calcium loading. These results are in agreement with the knowledge that loss of mineralization inhibitors is crucial for promoting EV mineralization. 5, 15 Like previously shown for MGP, GRP is loaded in noncalcifying EVs and absent in high calcium-loaded vesicles, suggesting GRP as an important mineralization inhibitor highly related to the EV mineralization process. Furthermore, it is possible that inhibition of EV calcification capacity might occur constitutively via a GRP-MGP-fetuin-A containing complex, forming a potent inhibitory system. In concordance, an MGP-fetuin-A complex was described in chondrocyte-derived EVs, 12 and it was proposed that the calcification inhibitory function of the MGP-fetuin-A complex in circulation results from the strong calcium phosphate binding capacity of these proteins. 13 The GRP-MGPfetuin-A complex was detected at the sites of calcification and associated with known EV components, such as annexin A2 and S100A9, 15, 39 and ECM calcification is well known to be initiated with the deposition of basic calcium phosphatecontaining vesicles. 5, 15 Considering the characterization of VSMC-derived vesicles loaded with GRP and MGP, it could be suggested that those were mainly exosomes, as previously suggested for MGP-loaded EVs because of identification of proteins from endosomal origin. 15 Additional functional studies altering endogenous GRP, both by knockdown or gain of function experiments, will be crucial to definitively establish the GRP mechanism of action in VC and will bring new knowledge on the characterization of EV biogenesis, mechanisms of protein loading, and mineralization-related regulation.
From a research point of view, our study was pioneer in establishing GRP as a key factor involved in cardiovascular calcification, providing new data in the field of CAVD. Although it provides new insights into the GRP function as a calcification inhibitor, probably through mechanisms involving the MGP-fetuin-A calcification inhibitory system, acting on the inhibition of EV mineralization capacity, it raises new and important questions requiring further investigation.
From a clinical perspective, our work reinforces the notion that special care should be given to the widely used anticoagulant agents, such as warfarin, acting as vitamin K antagonists 40 and interfering with MGP and GRP functionalities. Further studies aiming to correlate circulating levels and γ-carboxylation status of GRP with the degree of calcification and disease progression are currently in progress and will enable us to evaluate the potential use of GRP as an additional marker for ectopic calcification.
For the first time, Gla-rich protein (GRP) has been demonstrated to be an important component of the cardiovascular system highly associated with calcification processes. We report that GRP expression and accumulation are upregulated with calcification, in both vascular and valvular tissues, and potentially involved in the transdifferentiation of resident cells into osteochondrogenic secreting cells. We show that exogenous γ-carboxylated GRP is able to inhibit calcification in an aortic ex vivo experimental model by maintaining cells in a contractile phenotype, whereas endogenous GRP is involved in extracellular vesicle mineralization competence, probably as part of a matrix Gla proteinfetuin-A complex. These findings provide important new molecular information about cardiovascular calcification and establish GRP as a novel player in calcification inhibition. These results indicate that the vitamin K effect as a vascular health protective agent may involve GRP functionality and that special care should be given to the widely used anticoagulant agents, such as warfarin, acting as vitamin K antagonists.
Significance
